Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Por:
Medina, A, Puig, N, Flores-Montero, J, Jimenez, C, Sarasquete, ME, Garcia-Alvarez, M, Prieto-Conde, I, Chillon, C, Alcoceba, M, Gutierrez, NC, Oriol, A, Rosinol, L, Blade, J, Gironella, M, Hernandez, MT, Gonzalez-Calle, V, Cedena, MT, Paiva, B, San-Miguel, JF, Lahuerta, JJ, Mateos, MV, Martinez-Lopez, J, Orfao, A, Gonzalez, M and Garcia-Sanz, R
Publicada:
30 oct 2020
Ahead of Print:
30 oct 2020
Resumen:
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack (R)), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R-2 = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09-0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06-0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
Filiaciones:
Medina, A:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Puig, N:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Flores-Montero, J:
USAL CSIC, Ctr Invest Canc IBMCC, CIBERONC, Salamanca, Spain
Jimenez, C:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Sarasquete, ME:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Garcia-Alvarez, M:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Prieto-Conde, I:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Chillon, C:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Alcoceba, M:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Gutierrez, NC:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol ICO, Inst Josep Carreras, Badalona, Spain
Rosinol, L:
Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Blade, J:
Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Gironella, M:
Hosp Valle De Hebron, Barcelona, Spain
Hernandez, MT:
Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
Gonzalez-Calle, V:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Cedena, MT:
Univ Complutense, CNIO, I 12, Hosp 12 Octubre, Madrid, Spain
Paiva, B:
Clin Univ Navarra CUN, CIBERONC, IDISNA, Ctr Invest Med Aplicada, Pamplona, Spain
San-Miguel, JF:
Clin Univ Navarra CUN, CIBERONC, IDISNA, Ctr Invest Med Aplicada, Pamplona, Spain
Lahuerta, JJ:
Univ Complutense, CNIO, I 12, Hosp 12 Octubre, Madrid, Spain
Mateos, MV:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Martinez-Lopez, J:
Univ Complutense, CNIO, I 12, Hosp 12 Octubre, Madrid, Spain
Orfao, A:
USAL CSIC, Ctr Invest Canc IBMCC, CIBERONC, Salamanca, Spain
Gonzalez, M:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
Garcia-Sanz, R:
Hosp Univ Salamanca, CIC IBMCC USAL CSIC, Dept Hematol, HUSA IBSAL,CIBERONC, Salamanca, Spain
gold, Green Published
|